ABL Bio Inc
KOSDAQ:298380
ABL Bio Inc
Free Cash Flow
ABL Bio Inc
Free Cash Flow Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Free Cash Flow
-₩78.5B
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Free Cash Flow
₩418.2B
|
CAGR 3-Years
53%
|
CAGR 5-Years
15%
|
CAGR 10-Years
21%
|
|
|
SK Bioscience Co Ltd
KRX:302440
|
Free Cash Flow
-₩300.2B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
H
|
Hugel Inc
KOSDAQ:145020
|
Free Cash Flow
₩103.8B
|
CAGR 3-Years
25%
|
CAGR 5-Years
18%
|
CAGR 10-Years
N/A
|
|
|
P
|
PharmaResearch Co Ltd
KOSDAQ:214450
|
Free Cash Flow
₩93.4B
|
CAGR 3-Years
47%
|
CAGR 5-Years
203%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Free Cash Flow
-₩11.3B
|
CAGR 3-Years
34%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
ABL Bio Inc
Glance View
ABL Bio, Inc. engages in the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2018-12-19. The major products include anti-angiogenesis antibodies anti-tumor targeting antibodies, T cell engager bispecific antibodies (TCEs), dual immune cell targeting bispecific antibodies (DICs), novel immune cell targeting antibodies (NICs), brain disease dual antibodies, antibody-drug conjugates (ADCs) , among others.
See Also
What is ABL Bio Inc's Free Cash Flow?
Free Cash Flow
-78.5B
KRW
Based on the financial report for Dec 31, 2024, ABL Bio Inc's Free Cash Flow amounts to -78.5B KRW.
What is ABL Bio Inc's Free Cash Flow growth rate?
Free Cash Flow CAGR 5Y
-23%
Over the last year, the Free Cash Flow growth was -129%. The average annual Free Cash Flow growth rates for ABL Bio Inc have been -23% over the past three years , -23% over the past five years .
You don't have any saved screeners yet